ATR inhibitors target DNA damage repair with promising efficacy in solid tumors

Results of a recent Phase I trial investigating a novel ATR inhibitor in solid tumors, conducted at the Institute of Cancer Research (ICR; London, UK), have demonstrated huge benefit against advanced, heavily pretreated cancers. The new drug candidate, BAY1895344, developed by Bayer (Leverkusen, Germany) who also sponsored the trial, was shown to be well-tolerated and stopped growth in more than half of participants. Although the aim of the trial was to evaluate safety and dosing, the results show that ATR inhibitors could be a promising class of drugs for tumors with ATM mutations – a DNA damage repair pathway gene....